Details of the Drug
General Information of Drug (ID: DMZBIC3)
Drug Name |
BAS-01373578
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
BAS-01373578; CHEMBL206575; (4Z)-4-[[5-(3-chloro-4-methylphenyl)furan-2-yl]methylidene]-1-(3,4-dimethylphenyl)pyrazolidine-3,5-dione; (4Z)-4-{[5-(3-chloro-4-methylphenyl)furan-2-yl]methylidene}-1-(3,4-dimethylphenyl)pyrazolidine-3,5-dione; AC1LWF8S; MolPort-030-043-249; MolPort-001-963-180; ZINC4471294; STL387426; STL383260; BDBM50187574; AKOS025249675; AKOS000447221; BAS 01373578; 4-((5-(3-chloro-4-methylphenyl)furan-2-yl)methylene)-1-(3,4-dimethylphenyl)pyrazolidine-3,5-dione
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 1 | Molecular Weight (mw) | 406.9 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 5.3 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||||||||